From Mind To Market - Boehringer Ingelheim

R &D at Boehringer Ingelheim
As a research-driven pharmaceutical company,
Boehringer Ingelheim is committed to the goal
of discovering and developing products which
represent high therapeutic value for patients,
physicians and health care providers.
R&D Centers are located in Biberach, Ger-
many, Ridgefield, USA; Vienna, Austria; Laval,
Canada; and Kawanishi, Japan. Our R&D activities
embrace the therapeutic areas of respiratory,
cardiovascular, metabolism, virology, central nervous
system, urology, immunology and oncology.
Boehringer Ingelheim’s R&D focuses on identifying
and developing new chemical entities and
new biological entities, such as therapeutic proteins
or gene therapies. Projects from the latter
category draw particular advantage from our
in-house biopharmaceutical manufacturing
expertise.
All R&D in Boehringer Ingelheim’s therapeutic
areas are supported by in-licensing for early and
late stage innovative pharmaceutical and biopharmaceutical
products.
In-licensing projects are evaluated in a short time
period and licensing deals are tailored according
to a partner’s individual needs. Together with
our capabilities in process science we can offer
attractive solutions for our licensors.
Therefore, for biopharmaceuticals, an integrated
approach ranging from product development to
marketing is highly attractive for the licensor.
In collaboration with our strategic partners and
from our own research efforts, we currently have
a number of promising compounds at various
stages of development.
Our areas of in-licensing interest:
- Respiratory - CNS
- Cardiovascular - Urology
- Metabolism - Immunology
- Virology - Oncology
23